TREM2 Modulator Therapy

Migration, Crosslink

📖

TREM2 Modulator Therapy

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-trem2-modulator-therap

📖 Wiki Page

therapeutic1556 wordssynced 2026-04-02

TREM2 Modulator Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Modulator Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Wang et al., 2016</td>
<td>5xFAD</td>
</tr>
<tr>
<td class="label">Lee et al., 2018</td>
<td>APP/PS1</td>
</tr>
<tr>
<td class="label">Shi et al., 2019</td>
<td>5xFAD</td>
</tr>
<tr>
<td class="label">Schlepckow et al., 2020</td>
<td>5xFAD</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Matrix</td>
</tr>
<tr>
<td class="label">sTREM2</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">TREM2 expression</td>
<td>PET</td>
</tr>
<tr>
<td class="label">CSF cytokines</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Amyloid/tau</td>
<td>CSF/PET</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">INVOKE-2</td>
<td>AL002</td>
</tr>
<tr>
<td class="label">AL002 Phase 1</td>
<td>AL002</td>
</tr>
<tr>
<td class="label">JNJ-7524</td>
<td>JNJ-7524</td>
</tr>
</table>

...

TREM2 Modulator Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Modulator Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Wang et al., 2016</td>
<td>5xFAD</td>
</tr>
<tr>
<td class="label">Lee et al., 2018</td>
<td>APP/PS1</td>
</tr>
<tr>
<td class="label">Shi et al., 2019</td>
<td>5xFAD</td>
</tr>
<tr>
<td class="label">Schlepckow et al., 2020</td>
<td>5xFAD</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Matrix</td>
</tr>
<tr>
<td class="label">sTREM2</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">TREM2 expression</td>
<td>PET</td>
</tr>
<tr>
<td class="label">CSF cytokines</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Amyloid/tau</td>
<td>CSF/PET</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">INVOKE-2</td>
<td>AL002</td>
</tr>
<tr>
<td class="label">AL002 Phase 1</td>
<td>AL002</td>
</tr>
<tr>
<td class="label">JNJ-7524</td>
<td>JNJ-7524</td>
</tr>
</table>

[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) modulator therapy represents one of the most promising approaches for treating Alzheimer's disease (AD) by targeting microglial function. Unlike approaches that directly target [amyloid-beta](/proteins/amyloid-beta) or [tau](/proteins/tau), TREM2 modulators aim to restore the phagocytic and protective functions of [microglia](/cell-types/microglia-neuroinflammation), the brain's immune cells.

Overview

TREM2 is a cell-surface receptor expressed primarily on microglia in the central nervous system. It plays a critical role in microglial survival, proliferation, phagocytosis, and the formation of disease-associated microglia (DAM) [@guerreiro2013]. Rare coding variants in TREM2 (particularly R47H) increase Alzheimer's disease risk by approximately 3-fold, comparable to the effect of APOE4 [@jonsson2013]. This genetic evidence strongly supports TREM2 as a therapeutic target.

The fundamental therapeutic rationale is that enhancing TREM2 signaling could restore microglial function, leading to improved clearance of pathological proteins, reduced neuroinflammation, and ultimately slower disease progression.

TREM2 Biology in Microglia

Receptor Structure and Signaling

TREM2 is a type I transmembrane receptor consisting of:

An extracellular immunoglobulin-like V-type domain that binds ligands
A transmembrane domain with a charged residue for adaptor protein association
A short cytoplasmic tail that lacks intrinsic signaling motifs

TREM2 signals through association with DAP12 (TYROBP), an adaptor protein containing an immunoreceptor tyrosine-based activation motif (ITAM). Upon ligand binding, DAP12 becomes phosphorylated and activates SYK, which initiates downstream signaling cascades [@wang2015].

Mermaid diagram (expand to render)

Soluble TREM2 (sTREM2)

TREM2 undergoes proteolytic cleavage by ADAM10 and ADAM17 at the extracellular domain, releasing a soluble fragment (sTREM2) into the cerebrospinal fluid (CSF) and blood. sTREM2 has emerged as an important biomarker and potential therapeutic agent:

Biomarker: CSF sTREM2 levels are elevated in early AD and correlate with disease progression [@suarezcalvet2016]
Function: sTREM2 may act as a decoy receptor, modulating TREM2 signaling
Therapeutic potential: Recombinant sTREM2 has shown protective effects in preclinical models

The ratio of sTREM2 to membrane-bound TREM2 provides important diagnostic information about microglial activation status.

CSF1R Signaling Relationship

TREM2 signaling intersects with CSF1R (Colony Stimulating Factor 1 Receptor) pathways, which are crucial for microglial survival and proliferation:

CSF1R is the primary regulator of microglial survival and proliferation
TREM2 provides complementary signals for microglial metabolic fitness and phagocytic function
Combination therapy: Concurrent TREM2 and CSF1R modulation is being explored as a strategy to enhance microglial function comprehensively [@mancuso2019]

TREM2 Agonism vs Antagonism Debate

Arguments for Agonism

The majority of drug development programs focus on TREM2 agonism based on the following rationale:

Loss-of-function: TREM2 variants associated with AD are predominantly loss-of-function mutations

Genetic evidence: TREM2 deficiency worsens pathology in animal models

Microglial protection: Agonism promotes the DAM phenotype associated with neuroprotection

Agonists aim to:

Enhance phagocytosis of amyloid-beta and cellular debris
Promote microglial clustering around plaques
Support microglial metabolic function
Reduce toxic neuroinflammation

Arguments for Antagonism

Some researchers argue that TREM2 antagonism could be beneficial:

Chronic activation concerns: Prolonged TREM2 activation might lead to dysregulated inflammation

Plaque morphology: TREM2 activation alters plaque morphology but may not reduce plaque load

Timing matters: The role of TREM2 may differ across disease stages

Current clinical evidence predominantly supports agonism, but the debate continues and may be resolved with data from ongoing clinical trials.

Preclinical Evidence in AD Models

5xFAD Mouse Model

The 5xFAD mouse model (bearing 5 familial AD mutations) has been extensively used to study TREM2:

TREM2 deficiency: Results in reduced microglial clustering around amyloid plaques
Plaque morphology: More diffuse, less compacted plaques in TREM2 knockout mice
Cognitive deficits: Exacerbated memory deficits in TREM2-deficient mice
Therapeutic benefit: TREM2 agonistic antibodies improve microglial function and reduce synaptic loss [@schlepckow2020]

APP/PS1 Mouse Model

Similar findings have been observed in [APP](/entities/app-protein)/PS1 mice:

TREM2 expression increases around amyloid plaques
DAM genes are upregulated in response to amyloid pathology
TREM2 modulation affects plaque-associated microglia
Therapeutic intervention shows improved neuronal function [@lee2018]

Key Preclinical Studies

Clinical Candidates

AL002 (Alector/AbbVie)

AL002 is a humanized anti-TREM2 monoclonal antibody designed to act as an agonist:

Mechanism: Binds to TREM2 extracellular domain, promoting receptor clustering and signaling
Development status: Phase 2 clinical trials in early AD (clinicaltrials.gov: NCT04592874)
Rationale: Based on strong preclinical data showing enhanced microglial function
Clinical results: Phase 1 showed acceptable safety and target engagement biomarkers

JNJ-7524 (Johnson & Johnson)

JNJ-7524 is another anti-TREM2 antibody in development:

Mechanism: TREM2 agonistic antibody
Development status: Phase 1 clinical trials
Features: Designed for enhanced brain penetration
Strategy: Targeting early AD patients with evidence of microglial activation

Other Programs

Several other companies have TREM2 programs at various stages:

Acumen Pharmaceuticals: AC-842 (TREM2 agonist)
Caribou Biosciences: CARBON TREM2 program
ILDO: Various TREM2-targeting approaches

Small Molecule Approaches

While antibody-based approaches dominate, small molecule TREM2 modulators are also being explored:

Advantages of Small Molecules

Oral bioavailability
Better tissue distribution
Potentially lower cost of goods
Improved patient compliance

Challenges

TREM2 is a membrane receptor with complex ligand-binding requirements
Small molecules may not effectively mimic antibody-mediated receptor clustering
Limited progress in identifying brain-penetrant TREM2 agonists

Current Programs

Most small molecule programs remain in discovery stages, focusing on:

Modulating TREM2 cleavage
Targeting downstream signaling pathways
CSF1R/TREM2 combination approaches

Biomarker Strategy

sTREM2 as a Biomarker

Cerebrospinal fluid sTREM2 is a validated biomarker for:

Disease staging: Elevated in early AD, declining in later stages

Target engagement: Pharmacodynamic marker for TREM2-targeting therapies

Patient selection: May identify patients most likely to benefit from therapy

Clinical Implementation

Clinical Trial Status

INVOKE-2 Trial Failure (2025)

The INVOKE-2 Phase 2 trial (AL002, Alector/AbbVie) evaluating TREM2 agonist therapy for Alzheimer's disease did not meet its primary endpoints. This failure, published in Nature Medicine in October 2025 [@rethinking2025], has significant implications for the TREM2 therapeutic approach:

Trial result: INVOKE-2 failed to demonstrate cognitive benefit in early AD patients
Implications: The field is reconsidering TREM2 agonism as a therapeutic strategy
Possible reasons: Timing of intervention, patient selection, or mechanism limitations
Future directions: Need for biomarker-driven patient selection and combination approaches

This failure highlights the complexity of targeting microglial function in AD and suggests that TREM2 modulation may need to be combined with other therapeutic approaches.

Active Clinical Trials

Expected Outcomes

Primary endpoints in ongoing trials include:

Safety and tolerability
Change in cognitive function (ADAS-Cog13, CDR-SB)
Biomarker changes (CSF sTREM2, amyloid PET, tau PET)
Brain volume measurements

Safety Profile

Known Safety Considerations

Based on preclinical and early clinical data:

Peripheral myeloid cells: TREM2 is expressed on peripheral monocytes and macrophages

Immunological effects: Potential impact on immune cell function

Infusion reactions: Common with monoclonal antibodies

Long-term effects: Unknown with chronic dosing

Monitoring Strategies

Clinical trials implement comprehensive safety monitoring:

Regular hematological assessments
Cytokine profiling
Infection monitoring
Imaging for brain inflammation (ARIA-like effects)

Gene and Protein Pages

[TREM2 Gene](/genes/trem2) - Gene page with variant information
[TREM2 Protein](/proteins/trem2-protein) - Protein structure and function
[TYROBP Gene](/genes/tyrobp) - DAP12 adaptor protein

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease) - Primary indication
[Alzheimer's Disease Pathophysiology](/mechanisms/alzheimers-pathophysiology) - Disease mechanisms

Mechanism Pages

[Microglial Pathways](/mechanisms/microglia-neuroinflammation) - Microglial biology
[TREM2 Signaling Pathway](/mechanisms/trem2-microglia-pathway) - Detailed signaling
[Neuroinflammation in AD](mechanisms/neuroinflammation) - Inflammation mechanisms
[Disease-Associated Microglia](/cell-types/disease-associated-microglia) - DAM phenotype

Treatment Pages

[TREM2 Agonists](treatments/trem2-agonists) - Related approach
[Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics) - Complementary approach
[Amyloid Vaccines](/therapeutics/amyloid-vaccines) - Complementary approach
[Neuroinflammation Treatments](/therapeutics/anti-inflammatory-therapy-neurodegeneration) - Related target

Biomarker Pages

[CSF Biomarkers](/biomarkers/cerebrospinal-fluid-biomarkers) - CSF analysis
[sTREM2 Biomarker](/biomarkers/strem2-soluble-trem2) - Specific biomarker

Future Directions

Combination Therapies

Emerging strategies include:

TREM2 modulators + amyloid-targeting agents
TREM2 modulators + anti-tau therapies
TREM2 + CSF1R combination
TREM2 + complement inhibitors

Personalized Medicine

Future developments may enable:

Genetic stratification based on TREM2 variants
Biomarker-driven patient selection
Stage-specific treatment approaches

slug	therapeutics-trem2-modulator-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-83f39f2e2f54
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-trem2-modulator-therapy'}
_schema_version	1

📗 Cite This Artifact

TREM2 Modulator Therapy

TREM2 Modulator Therapy

TREM2 Modulator Therapy

Overview

TREM2 Biology in Microglia

Receptor Structure and Signaling

Soluble TREM2 (sTREM2)

CSF1R Signaling Relationship

TREM2 Agonism vs Antagonism Debate

Arguments for Agonism

Arguments for Antagonism

Preclinical Evidence in AD Models

5xFAD Mouse Model

APP/PS1 Mouse Model

Key Preclinical Studies

Clinical Candidates

AL002 (Alector/AbbVie)

JNJ-7524 (Johnson & Johnson)

Other Programs

Small Molecule Approaches

Advantages of Small Molecules

Challenges

Current Programs

Biomarker Strategy

sTREM2 as a Biomarker

Clinical Implementation

Clinical Trial Status

INVOKE-2 Trial Failure (2025)

Active Clinical Trials

Expected Outcomes

Safety Profile

Known Safety Considerations

Monitoring Strategies

Cross-Links to Related Pages

Gene and Protein Pages

Disease Pages

Mechanism Pages

Treatment Pages

Biomarker Pages

Future Directions

Combination Therapies

Personalized Medicine

See Also

Related Hypotheses

💬 Discussion